Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 156 | 2024 | 694 | 27.140 |
Why?
|
Anti-HIV Agents | 42 | 2024 | 155 | 6.940 |
Why?
|
Neoplasms | 22 | 2024 | 438 | 4.860 |
Why?
|
Humans | 235 | 2024 | 17611 | 4.380 |
Why?
|
Adult | 155 | 2024 | 7598 | 4.140 |
Why?
|
Male | 175 | 2024 | 10008 | 4.090 |
Why?
|
CD4 Lymphocyte Count | 59 | 2024 | 178 | 3.990 |
Why?
|
Antiretroviral Therapy, Highly Active | 27 | 2020 | 93 | 3.880 |
Why?
|
Female | 176 | 2024 | 12608 | 3.800 |
Why?
|
Middle Aged | 134 | 2024 | 7911 | 3.800 |
Why?
|
Acquired Immunodeficiency Syndrome | 15 | 2023 | 63 | 3.700 |
Why?
|
Cohort Studies | 83 | 2024 | 2570 | 3.390 |
Why?
|
Viral Load | 32 | 2024 | 135 | 3.370 |
Why?
|
Anti-Retroviral Agents | 18 | 2023 | 80 | 3.070 |
Why?
|
Uterine Cervical Neoplasms | 11 | 2022 | 119 | 2.740 |
Why?
|
Risk Factors | 55 | 2024 | 3325 | 2.250 |
Why?
|
California | 43 | 2024 | 2284 | 2.130 |
Why?
|
Mouth Neoplasms | 4 | 2020 | 9 | 2.080 |
Why?
|
HIV-1 | 18 | 2017 | 70 | 2.080 |
Why?
|
Hepatitis C | 10 | 2023 | 65 | 2.070 |
Why?
|
Transgender Persons | 11 | 2024 | 38 | 1.970 |
Why?
|
Pre-Exposure Prophylaxis | 8 | 2024 | 19 | 1.900 |
Why?
|
Aged | 50 | 2024 | 6095 | 1.880 |
Why?
|
Critical Illness | 4 | 2015 | 50 | 1.870 |
Why?
|
Alcohol Drinking | 7 | 2021 | 368 | 1.860 |
Why?
|
Substance-Related Disorders | 11 | 2024 | 434 | 1.750 |
Why?
|
United States | 51 | 2024 | 3956 | 1.630 |
Why?
|
Leukoplakia, Oral | 3 | 2020 | 3 | 1.590 |
Why?
|
Continuity of Patient Care | 7 | 2022 | 105 | 1.580 |
Why?
|
Incidence | 33 | 2021 | 1255 | 1.580 |
Why?
|
Retrospective Studies | 33 | 2024 | 2447 | 1.570 |
Why?
|
Life Expectancy | 4 | 2020 | 33 | 1.520 |
Why?
|
Coinfection | 7 | 2023 | 30 | 1.500 |
Why?
|
Dementia | 2 | 2024 | 106 | 1.480 |
Why?
|
Delivery of Health Care, Integrated | 12 | 2021 | 531 | 1.470 |
Why?
|
Papillomavirus Infections | 8 | 2022 | 133 | 1.400 |
Why?
|
Papillomavirus Vaccines | 3 | 2020 | 113 | 1.360 |
Why?
|
Critical Care | 3 | 2014 | 71 | 1.340 |
Why?
|
Continental Population Groups | 3 | 2019 | 302 | 1.320 |
Why?
|
Young Adult | 41 | 2023 | 2427 | 1.320 |
Why?
|
Smoking | 6 | 2021 | 483 | 1.260 |
Why?
|
Adenocarcinoma | 4 | 2022 | 172 | 1.240 |
Why?
|
Drug Prescriptions | 6 | 2023 | 151 | 1.240 |
Why?
|
Medication Adherence | 6 | 2020 | 244 | 1.240 |
Why?
|
Reverse Transcriptase Inhibitors | 7 | 2024 | 24 | 1.240 |
Why?
|
Carcinoma, Squamous Cell | 5 | 2017 | 55 | 1.220 |
Why?
|
Healthcare Disparities | 5 | 2018 | 201 | 1.210 |
Why?
|
Socioeconomic Factors | 8 | 2024 | 630 | 1.200 |
Why?
|
Myocardial Infarction | 5 | 2024 | 238 | 1.170 |
Why?
|
Sarcoma, Kaposi | 4 | 2021 | 12 | 1.110 |
Why?
|
Ethnic Groups | 5 | 2021 | 485 | 1.100 |
Why?
|
Laryngoscopy | 3 | 2015 | 3 | 1.100 |
Why?
|
Pain | 8 | 2024 | 79 | 1.100 |
Why?
|
Adolescent | 41 | 2024 | 3651 | 1.050 |
Why?
|
RNA, Viral | 18 | 2024 | 64 | 1.040 |
Why?
|
Skin Neoplasms | 3 | 2017 | 57 | 1.020 |
Why?
|
Video-Assisted Surgery | 2 | 2015 | 2 | 1.010 |
Why?
|
Intubation, Intratracheal | 2 | 2015 | 6 | 1.000 |
Why?
|
HIV | 10 | 2023 | 26 | 1.000 |
Why?
|
Carcinoma, Basal Cell | 2 | 2017 | 24 | 0.990 |
Why?
|
Insurance, Health | 5 | 2020 | 181 | 0.990 |
Why?
|
Proportional Hazards Models | 21 | 2024 | 709 | 0.990 |
Why?
|
Papillomaviridae | 6 | 2022 | 52 | 0.980 |
Why?
|
Hypertension | 4 | 2024 | 500 | 0.970 |
Why?
|
Internal Medicine | 2 | 2014 | 20 | 0.970 |
Why?
|
Video Recording | 2 | 2014 | 12 | 0.960 |
Why?
|
Education, Medical, Graduate | 2 | 2014 | 18 | 0.960 |
Why?
|
Bacteremia | 1 | 2024 | 12 | 0.950 |
Why?
|
Antiviral Agents | 4 | 2022 | 94 | 0.950 |
Why?
|
North America | 20 | 2024 | 42 | 0.940 |
Why?
|
Lymphoma, AIDS-Related | 4 | 2012 | 18 | 0.940 |
Why?
|
Primary Health Care | 6 | 2024 | 766 | 0.930 |
Why?
|
Streptococcal Infections | 1 | 2024 | 22 | 0.930 |
Why?
|
Suicidal Ideation | 3 | 2024 | 100 | 0.930 |
Why?
|
Analgesics, Opioid | 8 | 2024 | 243 | 0.920 |
Why?
|
Prevalence | 20 | 2024 | 884 | 0.910 |
Why?
|
Mass Screening | 8 | 2022 | 661 | 0.900 |
Why?
|
Anus Neoplasms | 5 | 2020 | 26 | 0.890 |
Why?
|
Program Evaluation | 2 | 2014 | 223 | 0.890 |
Why?
|
Hallucinogens | 1 | 2024 | 23 | 0.880 |
Why?
|
Mental Health | 7 | 2023 | 165 | 0.870 |
Why?
|
HIV Seropositivity | 11 | 2017 | 31 | 0.870 |
Why?
|
Cervical Intraepithelial Neoplasia | 3 | 2019 | 16 | 0.870 |
Why?
|
Risk Assessment | 13 | 2024 | 1097 | 0.860 |
Why?
|
Early Detection of Cancer | 8 | 2022 | 501 | 0.860 |
Why?
|
Fractures, Bone | 1 | 2023 | 91 | 0.850 |
Why?
|
Alcoholism | 4 | 2021 | 347 | 0.850 |
Why?
|
Fasciitis, Necrotizing | 1 | 2022 | 1 | 0.830 |
Why?
|
Anti-Bacterial Agents | 1 | 2024 | 140 | 0.830 |
Why?
|
Abdominal Wall | 1 | 2022 | 2 | 0.830 |
Why?
|
Opioid-Related Disorders | 2 | 2024 | 167 | 0.820 |
Why?
|
African Continental Ancestry Group | 4 | 2018 | 162 | 0.820 |
Why?
|
Health Services Accessibility | 6 | 2020 | 289 | 0.810 |
Why?
|
Cardiovascular Diseases | 5 | 2024 | 598 | 0.810 |
Why?
|
Cannabis | 1 | 2024 | 78 | 0.810 |
Why?
|
Comorbidity | 11 | 2024 | 594 | 0.760 |
Why?
|
Electronic Health Records | 6 | 2024 | 681 | 0.760 |
Why?
|
Tobacco Smoking | 1 | 2021 | 20 | 0.730 |
Why?
|
Alphapapillomavirus | 1 | 2020 | 13 | 0.710 |
Why?
|
Canada | 20 | 2023 | 66 | 0.710 |
Why?
|
Precancerous Conditions | 1 | 2020 | 47 | 0.710 |
Why?
|
Unsafe Sex | 1 | 2020 | 19 | 0.710 |
Why?
|
Prostatic Neoplasms | 4 | 2017 | 262 | 0.680 |
Why?
|
Condylomata Acuminata | 6 | 2009 | 23 | 0.680 |
Why?
|
Case-Control Studies | 10 | 2020 | 1115 | 0.680 |
Why?
|
Treatment Outcome | 19 | 2019 | 1259 | 0.660 |
Why?
|
Motivational Interviewing | 1 | 2019 | 33 | 0.650 |
Why?
|
Sexual and Gender Minorities | 3 | 2024 | 27 | 0.650 |
Why?
|
Text Messaging | 1 | 2019 | 29 | 0.640 |
Why?
|
Follow-Up Studies | 13 | 2020 | 1210 | 0.640 |
Why?
|
Lymphoma, Non-Hodgkin | 4 | 2015 | 24 | 0.640 |
Why?
|
Risk | 8 | 2021 | 516 | 0.630 |
Why?
|
HIV Protease Inhibitors | 4 | 2024 | 16 | 0.630 |
Why?
|
Smoking Cessation | 1 | 2020 | 193 | 0.620 |
Why?
|
Colorectal Neoplasms | 3 | 2020 | 613 | 0.620 |
Why?
|
Patient Compliance | 8 | 2017 | 298 | 0.620 |
Why?
|
Medical Record Linkage | 2 | 2015 | 38 | 0.610 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2018 | 8 | 0.600 |
Why?
|
Quality of Health Care | 1 | 2020 | 326 | 0.600 |
Why?
|
Mental Disorders | 4 | 2023 | 280 | 0.600 |
Why?
|
AIDS-Related Opportunistic Infections | 5 | 2016 | 17 | 0.600 |
Why?
|
Renal Insufficiency, Chronic | 4 | 2024 | 179 | 0.600 |
Why?
|
Prostate-Specific Antigen | 2 | 2016 | 75 | 0.600 |
Why?
|
Lung Neoplasms | 3 | 2017 | 255 | 0.600 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2017 | 15 | 0.590 |
Why?
|
Anxiety | 5 | 2023 | 150 | 0.580 |
Why?
|
End Stage Liver Disease | 4 | 2022 | 9 | 0.580 |
Why?
|
Common Variable Immunodeficiency | 1 | 2017 | 5 | 0.580 |
Why?
|
Hepacivirus | 6 | 2023 | 51 | 0.570 |
Why?
|
Heart Failure | 1 | 2022 | 396 | 0.570 |
Why?
|
Age Factors | 12 | 2019 | 917 | 0.560 |
Why?
|
Aged, 80 and over | 15 | 2021 | 1900 | 0.560 |
Why?
|
Cross-Sectional Studies | 13 | 2024 | 1322 | 0.560 |
Why?
|
Pneumonia | 1 | 2017 | 51 | 0.550 |
Why?
|
Syphilis | 2 | 2022 | 17 | 0.550 |
Why?
|
Prospective Studies | 15 | 2022 | 1267 | 0.540 |
Why?
|
Pneumococcal Infections | 1 | 2016 | 42 | 0.540 |
Why?
|
Dideoxynucleosides | 1 | 2016 | 8 | 0.540 |
Why?
|
Hepatitis B | 5 | 2023 | 42 | 0.530 |
Why?
|
Age Distribution | 8 | 2021 | 246 | 0.530 |
Why?
|
Pneumococcal Vaccines | 1 | 2016 | 64 | 0.530 |
Why?
|
Dyslipidemias | 2 | 2024 | 62 | 0.520 |
Why?
|
Hepatitis B, Chronic | 4 | 2022 | 27 | 0.520 |
Why?
|
Prognosis | 10 | 2024 | 606 | 0.520 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 171 | 0.510 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2015 | 6 | 0.500 |
Why?
|
Biomarkers, Tumor | 5 | 2017 | 142 | 0.500 |
Why?
|
Endoscopy | 2 | 2014 | 10 | 0.500 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 4 | 2017 | 14 | 0.500 |
Why?
|
Registries | 8 | 2018 | 471 | 0.500 |
Why?
|
Ablation Techniques | 1 | 2014 | 3 | 0.490 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2014 | 20 | 0.490 |
Why?
|
Papilloma | 2 | 2004 | 2 | 0.460 |
Why?
|
Depression | 4 | 2024 | 502 | 0.460 |
Why?
|
Liver Diseases | 4 | 2012 | 23 | 0.460 |
Why?
|
Blood Vessels | 1 | 2013 | 1 | 0.450 |
Why?
|
Ultrasonography, Interventional | 1 | 2013 | 4 | 0.450 |
Why?
|
Homosexuality, Male | 9 | 2024 | 38 | 0.450 |
Why?
|
Esophageal Neoplasms | 1 | 2014 | 115 | 0.450 |
Why?
|
Catheterization, Central Venous | 1 | 2013 | 12 | 0.450 |
Why?
|
Venous Thrombosis | 1 | 2013 | 21 | 0.440 |
Why?
|
Barrett Esophagus | 1 | 2014 | 114 | 0.440 |
Why?
|
Anemia | 2 | 2024 | 32 | 0.440 |
Why?
|
Hepatitis C, Chronic | 3 | 2021 | 64 | 0.440 |
Why?
|
Protease Inhibitors | 1 | 2012 | 5 | 0.420 |
Why?
|
Transsexualism | 3 | 2023 | 10 | 0.420 |
Why?
|
Longitudinal Studies | 5 | 2021 | 710 | 0.410 |
Why?
|
Pregnancy Complications, Infectious | 3 | 2021 | 136 | 0.400 |
Why?
|
Pandemics | 4 | 2023 | 287 | 0.400 |
Why?
|
Disease Progression | 6 | 2023 | 264 | 0.400 |
Why?
|
Stroke | 1 | 2014 | 311 | 0.390 |
Why?
|
Sex Factors | 6 | 2024 | 643 | 0.390 |
Why?
|
Nelfinavir | 1 | 2011 | 4 | 0.380 |
Why?
|
Proton Pump Inhibitors | 1 | 2011 | 24 | 0.370 |
Why?
|
Acne Vulgaris | 2 | 2021 | 8 | 0.360 |
Why?
|
HIV Seronegativity | 4 | 2007 | 9 | 0.360 |
Why?
|
Aging | 5 | 2022 | 161 | 0.360 |
Why?
|
Liver Neoplasms | 4 | 2021 | 40 | 0.350 |
Why?
|
Sexual Behavior | 4 | 2017 | 124 | 0.350 |
Why?
|
European Continental Ancestry Group | 5 | 2018 | 529 | 0.350 |
Why?
|
Gender Identity | 7 | 2024 | 36 | 0.340 |
Why?
|
Gemfibrozil | 1 | 2009 | 5 | 0.330 |
Why?
|
Hypolipidemic Agents | 1 | 2009 | 40 | 0.320 |
Why?
|
Erectile Dysfunction | 2 | 2019 | 24 | 0.320 |
Why?
|
Models, Theoretical | 2 | 2019 | 70 | 0.310 |
Why?
|
Hispanic Americans | 4 | 2021 | 404 | 0.310 |
Why?
|
Patient Protection and Affordable Care Act | 3 | 2020 | 42 | 0.310 |
Why?
|
Tenofovir | 3 | 2023 | 18 | 0.310 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2017 | 13 | 0.310 |
Why?
|
Epidemiologic Methods | 4 | 2010 | 81 | 0.300 |
Why?
|
Logistic Models | 8 | 2018 | 926 | 0.290 |
Why?
|
Drug Resistance, Viral | 2 | 2017 | 12 | 0.280 |
Why?
|
Military Personnel | 2 | 2006 | 12 | 0.280 |
Why?
|
Regression Analysis | 6 | 2015 | 297 | 0.280 |
Why?
|
Neoplasm Invasiveness | 3 | 2018 | 78 | 0.280 |
Why?
|
Prescriptions | 2 | 2024 | 27 | 0.280 |
Why?
|
Drug Therapy, Combination | 5 | 2021 | 114 | 0.280 |
Why?
|
Breast Neoplasms | 3 | 2021 | 949 | 0.270 |
Why?
|
Lymphocyte Activation | 2 | 2017 | 7 | 0.270 |
Why?
|
Human papillomavirus 16 | 1 | 2006 | 7 | 0.270 |
Why?
|
Insurance Coverage | 3 | 2024 | 106 | 0.270 |
Why?
|
Antibodies, Viral | 1 | 2006 | 65 | 0.260 |
Why?
|
Sexual Partners | 3 | 2020 | 37 | 0.260 |
Why?
|
Time Factors | 10 | 2017 | 1086 | 0.250 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 130 | 0.250 |
Why?
|
Immune Tolerance | 3 | 2017 | 6 | 0.240 |
Why?
|
Self-Injurious Behavior | 2 | 2023 | 44 | 0.240 |
Why?
|
Body Mass Index | 4 | 2018 | 958 | 0.240 |
Why?
|
Erythrocyte Indices | 1 | 2024 | 2 | 0.240 |
Why?
|
Condoms | 2 | 2020 | 33 | 0.240 |
Why?
|
Insurance, Life | 1 | 2024 | 1 | 0.240 |
Why?
|
Insurance, Disability | 1 | 2024 | 1 | 0.240 |
Why?
|
Administration, Intravenous | 1 | 2024 | 6 | 0.240 |
Why?
|
Kidney Failure, Chronic | 2 | 2017 | 147 | 0.240 |
Why?
|
Respiratory Tract Neoplasms | 1 | 2004 | 2 | 0.240 |
Why?
|
Administration, Oral | 1 | 2024 | 85 | 0.230 |
Why?
|
Demography | 4 | 2020 | 101 | 0.230 |
Why?
|
HIV Integrase Inhibitors | 2 | 2022 | 3 | 0.230 |
Why?
|
Glomerular Filtration Rate | 5 | 2023 | 153 | 0.230 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2021 | 26 | 0.230 |
Why?
|
Severity of Illness Index | 3 | 2021 | 454 | 0.220 |
Why?
|
Health Status Disparities | 2 | 2019 | 146 | 0.220 |
Why?
|
Vaccination | 2 | 2020 | 635 | 0.220 |
Why?
|
Lymphoma | 2 | 2017 | 6 | 0.220 |
Why?
|
Survival Analysis | 5 | 2016 | 215 | 0.220 |
Why?
|
Testosterone | 2 | 2021 | 22 | 0.220 |
Why?
|
Cognition | 1 | 2024 | 81 | 0.220 |
Why?
|
Laryngeal Neoplasms | 1 | 2003 | 2 | 0.220 |
Why?
|
AIDS Serodiagnosis | 1 | 2003 | 10 | 0.220 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2003 | 22 | 0.210 |
Why?
|
Raltegravir Potassium | 2 | 2022 | 9 | 0.210 |
Why?
|
RNA | 1 | 2022 | 12 | 0.210 |
Why?
|
Multivariate Analysis | 7 | 2017 | 568 | 0.210 |
Why?
|
Depressive Disorder | 4 | 2021 | 222 | 0.210 |
Why?
|
Genital Diseases, Female | 1 | 2002 | 9 | 0.210 |
Why?
|
Gastrostomy | 1 | 2022 | 3 | 0.210 |
Why?
|
Hormones | 1 | 2022 | 14 | 0.210 |
Why?
|
Gonorrhea | 1 | 2022 | 18 | 0.210 |
Why?
|
Medicare | 3 | 2019 | 202 | 0.210 |
Why?
|
Chlamydia Infections | 1 | 2022 | 25 | 0.210 |
Why?
|
Patient Readmission | 1 | 2024 | 163 | 0.200 |
Why?
|
Self Report | 1 | 2024 | 251 | 0.200 |
Why?
|
Surveys and Questionnaires | 5 | 2024 | 1309 | 0.200 |
Why?
|
Sexually Transmitted Diseases | 1 | 2022 | 54 | 0.200 |
Why?
|
Neoplasm Grading | 2 | 2019 | 48 | 0.200 |
Why?
|
Infant, Newborn | 7 | 2024 | 844 | 0.200 |
Why?
|
Chronic Disease | 5 | 2020 | 428 | 0.200 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2004 | 244 | 0.200 |
Why?
|
Immunosuppression | 2 | 2020 | 7 | 0.200 |
Why?
|
Odds Ratio | 5 | 2017 | 671 | 0.190 |
Why?
|
Genetic Variation | 2 | 2019 | 77 | 0.190 |
Why?
|
Research Design | 3 | 2020 | 374 | 0.190 |
Why?
|
Bayes Theorem | 4 | 2022 | 70 | 0.190 |
Why?
|
Biopsy | 4 | 2017 | 74 | 0.190 |
Why?
|
Homeless Persons | 1 | 2021 | 26 | 0.190 |
Why?
|
Housing | 1 | 2021 | 39 | 0.190 |
Why?
|
Social Stigma | 1 | 2021 | 18 | 0.190 |
Why?
|
Diabetes Mellitus | 2 | 2024 | 487 | 0.190 |
Why?
|
Europe | 4 | 2024 | 42 | 0.180 |
Why?
|
District of Columbia | 1 | 2020 | 17 | 0.180 |
Why?
|
Drug Resistance, Multiple, Viral | 2 | 2011 | 6 | 0.180 |
Why?
|
Reference Values | 3 | 2018 | 91 | 0.180 |
Why?
|
Weight Gain | 2 | 2020 | 173 | 0.180 |
Why?
|
Sex Distribution | 3 | 2016 | 190 | 0.180 |
Why?
|
Child | 12 | 2021 | 2474 | 0.180 |
Why?
|
Cooperative Behavior | 3 | 2016 | 91 | 0.180 |
Why?
|
Validation Studies as Topic | 1 | 2020 | 11 | 0.180 |
Why?
|
Benchmarking | 1 | 2020 | 46 | 0.180 |
Why?
|
Pregnant Women | 1 | 2021 | 45 | 0.180 |
Why?
|
Computer User Training | 1 | 2000 | 2 | 0.180 |
Why?
|
Computer Literacy | 1 | 2000 | 2 | 0.180 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2020 | 2 | 0.180 |
Why?
|
Alcohol-Related Disorders | 1 | 2021 | 55 | 0.170 |
Why?
|
Kaplan-Meier Estimate | 3 | 2015 | 129 | 0.170 |
Why?
|
Students, Medical | 1 | 2000 | 18 | 0.170 |
Why?
|
Viremia | 3 | 2020 | 9 | 0.170 |
Why?
|
Delivery of Health Care | 4 | 2022 | 415 | 0.170 |
Why?
|
Practice Patterns, Physicians' | 1 | 2023 | 330 | 0.170 |
Why?
|
Kidney Transplantation | 2 | 2017 | 29 | 0.170 |
Why?
|
SEER Program | 3 | 2017 | 91 | 0.170 |
Why?
|
Sexually Transmitted Diseases, Bacterial | 1 | 2019 | 3 | 0.170 |
Why?
|
Biomarkers | 3 | 2017 | 301 | 0.170 |
Why?
|
Diplopia | 1 | 1999 | 1 | 0.170 |
Why?
|
Sensory Deprivation | 1 | 1999 | 1 | 0.170 |
Why?
|
Vision, Binocular | 1 | 1999 | 1 | 0.170 |
Why?
|
Macula Lutea | 1 | 1999 | 2 | 0.170 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2020 | 39 | 0.170 |
Why?
|
Disease Transmission, Infectious | 1 | 2019 | 13 | 0.170 |
Why?
|
Virus Replication | 2 | 2011 | 12 | 0.170 |
Why?
|
Predictive Value of Tests | 6 | 2017 | 351 | 0.170 |
Why?
|
Retinal Diseases | 1 | 1999 | 16 | 0.170 |
Why?
|
Suicide, Attempted | 1 | 2020 | 96 | 0.170 |
Why?
|
Coronavirus Infections | 1 | 2020 | 49 | 0.160 |
Why?
|
Sigmoidoscopy | 1 | 2019 | 65 | 0.160 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 56 | 0.160 |
Why?
|
Reproducibility of Results | 1 | 2019 | 381 | 0.160 |
Why?
|
Cost-Benefit Analysis | 1 | 2019 | 250 | 0.160 |
Why?
|
Chronic Pain | 1 | 2020 | 127 | 0.150 |
Why?
|
Medical Records | 1 | 2018 | 100 | 0.150 |
Why?
|
Adenoma | 1 | 2019 | 93 | 0.150 |
Why?
|
Sex Reassignment Surgery | 1 | 2017 | 2 | 0.150 |
Why?
|
Referral and Consultation | 1 | 2019 | 167 | 0.150 |
Why?
|
United States Dept. of Health and Human Services | 2 | 2014 | 7 | 0.150 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2018 | 95 | 0.150 |
Why?
|
Behavior Therapy | 1 | 2019 | 146 | 0.150 |
Why?
|
Cell Cycle Proteins | 2 | 2015 | 6 | 0.150 |
Why?
|
Apoptosis | 2 | 2015 | 10 | 0.150 |
Why?
|
B-Lymphocytes | 1 | 2017 | 4 | 0.150 |
Why?
|
Recurrence | 3 | 2012 | 186 | 0.150 |
Why?
|
Transcriptome | 1 | 2017 | 22 | 0.150 |
Why?
|
Gene Expression Profiling | 1 | 2017 | 34 | 0.150 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2017 | 748 | 0.150 |
Why?
|
Living Donors | 1 | 2017 | 3 | 0.150 |
Why?
|
Prostatectomy | 1 | 2017 | 75 | 0.150 |
Why?
|
Graft Rejection | 1 | 2017 | 5 | 0.140 |
Why?
|
Genomics | 1 | 2017 | 55 | 0.140 |
Why?
|
African Americans | 4 | 2021 | 472 | 0.140 |
Why?
|
Colonoscopy | 1 | 2019 | 251 | 0.140 |
Why?
|
Colonic Pouches | 1 | 2016 | 1 | 0.140 |
Why?
|
Anal Canal | 1 | 2016 | 7 | 0.140 |
Why?
|
Serogroup | 1 | 2016 | 10 | 0.140 |
Why?
|
Medicaid | 1 | 2018 | 186 | 0.140 |
Why?
|
Colitis, Ulcerative | 1 | 2016 | 9 | 0.140 |
Why?
|
Streptococcus pneumoniae | 1 | 2016 | 19 | 0.140 |
Why?
|
Patient Participation | 2 | 2015 | 133 | 0.140 |
Why?
|
Neoplasm Staging | 1 | 2018 | 325 | 0.140 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 368 | 0.140 |
Why?
|
Vaccines, Conjugate | 1 | 2016 | 59 | 0.140 |
Why?
|
Treatment Failure | 3 | 2012 | 35 | 0.130 |
Why?
|
Kallikreins | 1 | 2016 | 3 | 0.130 |
Why?
|
Internet | 2 | 2013 | 231 | 0.130 |
Why?
|
Anxiety Disorders | 3 | 2022 | 91 | 0.130 |
Why?
|
Risk Reduction Behavior | 1 | 2016 | 108 | 0.130 |
Why?
|
Disease Management | 1 | 2016 | 135 | 0.130 |
Why?
|
T-Lymphocyte Subsets | 1 | 2015 | 4 | 0.130 |
Why?
|
Macrophages | 1 | 2015 | 4 | 0.130 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2015 | 5 | 0.130 |
Why?
|
Health Status | 1 | 2017 | 298 | 0.130 |
Why?
|
Guideline Adherence | 1 | 2016 | 155 | 0.130 |
Why?
|
Child, Preschool | 8 | 2018 | 1409 | 0.130 |
Why?
|
APACHE | 1 | 2015 | 11 | 0.120 |
Why?
|
Hospitals, Teaching | 1 | 2015 | 17 | 0.120 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2015 | 4 | 0.120 |
Why?
|
National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division | 1 | 2014 | 5 | 0.120 |
Why?
|
Head and Neck Neoplasms | 1 | 2014 | 6 | 0.120 |
Why?
|
Pregnancy | 4 | 2021 | 1494 | 0.120 |
Why?
|
Patient Acceptance of Health Care | 2 | 2020 | 382 | 0.120 |
Why?
|
Infant | 7 | 2022 | 1171 | 0.120 |
Why?
|
Vaginal Smears | 4 | 2022 | 48 | 0.120 |
Why?
|
Healthcare Financing | 1 | 2013 | 4 | 0.110 |
Why?
|
Denmark | 2 | 2004 | 18 | 0.110 |
Why?
|
Government Programs | 1 | 2013 | 11 | 0.110 |
Why?
|
Leg | 1 | 2013 | 3 | 0.110 |
Why?
|
Ultrasonography | 1 | 2013 | 35 | 0.110 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2013 | 7 | 0.110 |
Why?
|
Interleukin-6 | 1 | 2013 | 25 | 0.110 |
Why?
|
Appointments and Schedules | 1 | 2013 | 26 | 0.110 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 6 | 0.110 |
Why?
|
Staphylococcal Infections | 1 | 2013 | 14 | 0.110 |
Why?
|
Bile Ducts | 2 | 1983 | 3 | 0.110 |
Why?
|
Lower Urinary Tract Symptoms | 1 | 2013 | 13 | 0.110 |
Why?
|
C-Reactive Protein | 1 | 2013 | 58 | 0.110 |
Why?
|
Office Visits | 1 | 2013 | 80 | 0.110 |
Why?
|
Immunocompromised Host | 1 | 2012 | 18 | 0.110 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2012 | 4 | 0.100 |
Why?
|
Melanoma | 1 | 2013 | 35 | 0.100 |
Why?
|
Herpesvirus 3, Human | 1 | 2012 | 44 | 0.100 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2012 | 51 | 0.100 |
Why?
|
Cell Count | 1 | 2012 | 10 | 0.100 |
Why?
|
Hepatitis, Viral, Human | 2 | 1985 | 4 | 0.100 |
Why?
|
Patient Selection | 1 | 2013 | 190 | 0.100 |
Why?
|
Tuberculosis | 1 | 2011 | 20 | 0.100 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2011 | 2 | 0.090 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 6 | 0.090 |
Why?
|
Herpes Zoster | 1 | 2012 | 82 | 0.090 |
Why?
|
Drug Interactions | 1 | 2011 | 20 | 0.090 |
Why?
|
Cytochrome P-450 CYP2C19 | 1 | 2011 | 4 | 0.090 |
Why?
|
Drug Administration Schedule | 5 | 2010 | 98 | 0.090 |
Why?
|
State Health Plans | 1 | 2010 | 35 | 0.090 |
Why?
|
Analgesics | 1 | 2010 | 27 | 0.090 |
Why?
|
Delayed Diagnosis | 1 | 2010 | 19 | 0.090 |
Why?
|
DNA, Viral | 3 | 2023 | 17 | 0.090 |
Why?
|
Fanconi Syndrome | 1 | 2010 | 4 | 0.090 |
Why?
|
Organophosphonates | 1 | 2010 | 7 | 0.090 |
Why?
|
Adenine | 1 | 2010 | 8 | 0.090 |
Why?
|
Likelihood Functions | 1 | 2010 | 44 | 0.090 |
Why?
|
Health Policy | 2 | 2024 | 122 | 0.090 |
Why?
|
Appendicitis | 1 | 2009 | 15 | 0.080 |
Why?
|
Quality Assurance, Health Care | 1 | 2011 | 169 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2021 | 27 | 0.080 |
Why?
|
Immunologic Surveillance | 1 | 2009 | 2 | 0.080 |
Why?
|
Urologic Diseases | 1 | 2009 | 6 | 0.080 |
Why?
|
Prescription Drugs | 1 | 2009 | 31 | 0.080 |
Why?
|
Hepatitis B virus | 3 | 2023 | 20 | 0.080 |
Why?
|
Obesity | 1 | 2015 | 837 | 0.080 |
Why?
|
Drug Overdose | 1 | 2010 | 56 | 0.080 |
Why?
|
Oligopeptides | 1 | 2008 | 6 | 0.080 |
Why?
|
Pyridines | 1 | 2008 | 9 | 0.080 |
Why?
|
Ritonavir | 1 | 2008 | 8 | 0.080 |
Why?
|
Genotype | 2 | 2011 | 227 | 0.080 |
Why?
|
Triglycerides | 1 | 2009 | 86 | 0.080 |
Why?
|
Mortality | 1 | 2009 | 117 | 0.080 |
Why?
|
Cholesterol, LDL | 1 | 2009 | 119 | 0.080 |
Why?
|
Anus Diseases | 2 | 2005 | 2 | 0.080 |
Why?
|
Cholestasis, Intrahepatic | 2 | 1990 | 2 | 0.080 |
Why?
|
Creatinine | 2 | 2023 | 65 | 0.070 |
Why?
|
Serotonin Uptake Inhibitors | 1 | 2008 | 71 | 0.070 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2009 | 121 | 0.070 |
Why?
|
Substance Abuse, Intravenous | 2 | 2021 | 33 | 0.070 |
Why?
|
Pharmacists | 1 | 2007 | 48 | 0.070 |
Why?
|
Blood Glucose | 1 | 2009 | 341 | 0.070 |
Why?
|
Liver | 3 | 2019 | 32 | 0.070 |
Why?
|
Immunohistochemistry | 2 | 2017 | 44 | 0.070 |
Why?
|
Muscle Contraction | 2 | 1997 | 4 | 0.070 |
Why?
|
HIV Antibodies | 1 | 2006 | 4 | 0.070 |
Why?
|
Risk-Taking | 1 | 2007 | 109 | 0.070 |
Why?
|
Repressor Proteins | 2 | 2019 | 13 | 0.070 |
Why?
|
Long-Term Care | 3 | 2010 | 22 | 0.070 |
Why?
|
Papanicolaou Test | 3 | 2016 | 37 | 0.060 |
Why?
|
Population Surveillance | 2 | 2017 | 263 | 0.060 |
Why?
|
Drug Utilization | 3 | 2010 | 127 | 0.060 |
Why?
|
Hospitalization | 2 | 2021 | 797 | 0.060 |
Why?
|
Vulvar Neoplasms | 1 | 2004 | 1 | 0.060 |
Why?
|
Hemoglobins | 1 | 2024 | 39 | 0.060 |
Why?
|
Mutation | 2 | 2017 | 128 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2007 | 375 | 0.060 |
Why?
|
Carcinoma | 1 | 2004 | 22 | 0.060 |
Why?
|
Kidney Function Tests | 2 | 2017 | 22 | 0.060 |
Why?
|
Multimorbidity | 1 | 2024 | 14 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 2 | 2015 | 6 | 0.060 |
Why?
|
Survival Rate | 2 | 2015 | 260 | 0.060 |
Why?
|
Multicenter Studies as Topic | 1 | 2004 | 86 | 0.060 |
Why?
|
DNA-Binding Proteins | 2 | 2015 | 29 | 0.060 |
Why?
|
Schools | 1 | 2024 | 85 | 0.060 |
Why?
|
Delivery, Obstetric | 1 | 2003 | 16 | 0.050 |
Why?
|
Military Medicine | 1 | 2003 | 1 | 0.050 |
Why?
|
Eligibility Determination | 1 | 2022 | 12 | 0.050 |
Why?
|
Kidney | 1 | 2023 | 52 | 0.050 |
Why?
|
Rilpivirine | 1 | 2022 | 1 | 0.050 |
Why?
|
Darunavir | 1 | 2022 | 4 | 0.050 |
Why?
|
Causality | 1 | 2022 | 40 | 0.050 |
Why?
|
Cause of Death | 1 | 2023 | 181 | 0.050 |
Why?
|
Bias | 1 | 2022 | 102 | 0.050 |
Why?
|
Quality of Life | 2 | 2020 | 507 | 0.050 |
Why?
|
Social Isolation | 1 | 2021 | 13 | 0.050 |
Why?
|
Vulnerable Populations | 1 | 2021 | 39 | 0.050 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2019 | 20 | 0.050 |
Why?
|
Income | 1 | 2021 | 90 | 0.050 |
Why?
|
San Francisco | 1 | 2020 | 64 | 0.050 |
Why?
|
Social Class | 1 | 2021 | 120 | 0.050 |
Why?
|
Respiratory System | 1 | 2020 | 3 | 0.040 |
Why?
|
MEDLINE | 1 | 2000 | 1 | 0.040 |
Why?
|
Oxazines | 1 | 2020 | 2 | 0.040 |
Why?
|
Piperazines | 1 | 2020 | 9 | 0.040 |
Why?
|
New York | 1 | 2000 | 20 | 0.040 |
Why?
|
Pyridones | 1 | 2020 | 8 | 0.040 |
Why?
|
Educational Measurement | 1 | 2000 | 18 | 0.040 |
Why?
|
Computer Communication Networks | 1 | 2000 | 12 | 0.040 |
Why?
|
Health Services for the Aged | 1 | 2020 | 14 | 0.040 |
Why?
|
Schools, Medical | 1 | 2000 | 16 | 0.040 |
Why?
|
Poverty | 1 | 2021 | 166 | 0.040 |
Why?
|
Betacoronavirus | 1 | 2020 | 35 | 0.040 |
Why?
|
Esophageal and Gastric Varices | 1 | 2019 | 4 | 0.040 |
Why?
|
Pregnancy Outcome | 1 | 2021 | 154 | 0.040 |
Why?
|
Eyeglasses | 1 | 1999 | 2 | 0.040 |
Why?
|
Cross-Cultural Comparison | 1 | 2019 | 15 | 0.040 |
Why?
|
South Africa | 1 | 2019 | 17 | 0.040 |
Why?
|
Liver Cirrhosis | 1 | 2019 | 35 | 0.040 |
Why?
|
Florida | 1 | 2019 | 8 | 0.040 |
Why?
|
Visual Acuity | 1 | 1999 | 21 | 0.040 |
Why?
|
Data Collection | 1 | 2020 | 256 | 0.040 |
Why?
|
Sustained Virologic Response | 1 | 2019 | 17 | 0.040 |
Why?
|
Organ Specificity | 1 | 2019 | 4 | 0.040 |
Why?
|
Gene Expression | 1 | 2019 | 23 | 0.040 |
Why?
|
Patient Safety | 1 | 2019 | 39 | 0.040 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 9 | 0.040 |
Why?
|
Machine Learning | 1 | 2019 | 46 | 0.040 |
Why?
|
Patient Preference | 1 | 2019 | 48 | 0.040 |
Why?
|
Melanocortins | 1 | 2018 | 2 | 0.040 |
Why?
|
Washington | 2 | 2010 | 374 | 0.040 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2018 | 3 | 0.040 |
Why?
|
Promoter Regions, Genetic | 1 | 2018 | 15 | 0.040 |
Why?
|
Alleles | 1 | 2018 | 84 | 0.040 |
Why?
|
Leptin | 1 | 2018 | 29 | 0.040 |
Why?
|
Georgia | 1 | 2018 | 26 | 0.040 |
Why?
|
Attention Deficit and Disruptive Behavior Disorders | 1 | 2018 | 10 | 0.040 |
Why?
|
Immunoglobulin Light Chains | 1 | 2017 | 1 | 0.040 |
Why?
|
Neoplasm Metastasis | 1 | 2017 | 31 | 0.040 |
Why?
|
Schizophrenia | 1 | 2018 | 77 | 0.040 |
Why?
|
Immunoglobulin G | 1 | 2017 | 29 | 0.040 |
Why?
|
Sequence Analysis, DNA | 1 | 2017 | 30 | 0.040 |
Why?
|
Graft Survival | 1 | 2017 | 3 | 0.040 |
Why?
|
Nephrectomy | 1 | 2017 | 6 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2017 | 23 | 0.040 |
Why?
|
ROC Curve | 1 | 2017 | 77 | 0.040 |
Why?
|
Adenosine Triphosphate | 1 | 1997 | 1 | 0.040 |
Why?
|
Muscle, Smooth, Vascular | 1 | 1997 | 2 | 0.040 |
Why?
|
Serotonin | 1 | 1997 | 6 | 0.040 |
Why?
|
Confounding Factors (Epidemiology) | 2 | 2009 | 86 | 0.040 |
Why?
|
Health Services Needs and Demand | 1 | 2017 | 93 | 0.040 |
Why?
|
History, 21st Century | 1 | 2017 | 24 | 0.040 |
Why?
|
Renal Insufficiency | 1 | 2016 | 13 | 0.040 |
Why?
|
Patient Outcome Assessment | 1 | 2017 | 28 | 0.030 |
Why?
|
Anastomosis, Surgical | 1 | 2016 | 7 | 0.030 |
Why?
|
Diagnosis, Dual (Psychiatry) | 1 | 2016 | 28 | 0.030 |
Why?
|
Qualitative Research | 1 | 2017 | 254 | 0.030 |
Why?
|
Hepatitis, Chronic | 1 | 2016 | 1 | 0.030 |
Why?
|
Developed Countries | 1 | 2016 | 6 | 0.030 |
Why?
|
Cost Sharing | 1 | 2016 | 30 | 0.030 |
Why?
|
Health Maintenance Organizations | 2 | 2008 | 417 | 0.030 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2016 | 22 | 0.030 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 3 | 0.030 |
Why?
|
Antigens, CD | 1 | 2015 | 5 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2015 | 6 | 0.030 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 107 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2016 | 102 | 0.030 |
Why?
|
Glomerular Mesangium | 1 | 1995 | 1 | 0.030 |
Why?
|
Ileum | 1 | 1975 | 1 | 0.030 |
Why?
|
Intestinal Neoplasms | 1 | 1975 | 2 | 0.030 |
Why?
|
Arginine Vasopressin | 1 | 1995 | 2 | 0.030 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 1995 | 3 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2015 | 61 | 0.030 |
Why?
|
Calcium | 1 | 1995 | 34 | 0.030 |
Why?
|
Glucose | 1 | 1995 | 30 | 0.030 |
Why?
|
Datasets as Topic | 1 | 2015 | 17 | 0.030 |
Why?
|
Autism Spectrum Disorder | 1 | 2018 | 163 | 0.030 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 2015 | 3 | 0.030 |
Why?
|
Interferon Regulatory Factors | 1 | 2015 | 3 | 0.030 |
Why?
|
Protein Kinase C beta | 1 | 2015 | 3 | 0.030 |
Why?
|
Hyaluronan Receptors | 1 | 2015 | 4 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2015 | 5 | 0.030 |
Why?
|
Immunoglobulin M | 1 | 2015 | 8 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 304 | 0.030 |
Why?
|
Hepatitis A | 3 | 1985 | 10 | 0.030 |
Why?
|
Crohn Disease | 2 | 1985 | 14 | 0.030 |
Why?
|
Acute Disease | 2 | 2005 | 142 | 0.030 |
Why?
|
Infant, Newborn, Diseases | 2 | 1977 | 34 | 0.030 |
Why?
|
Poisson Distribution | 1 | 2014 | 88 | 0.030 |
Why?
|
Antigens, Tumor-Associated, Carbohydrate | 1 | 1993 | 1 | 0.030 |
Why?
|
Carcinoembryonic Antigen | 1 | 1993 | 2 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2009 | 129 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 154 | 0.030 |
Why?
|
Hematologic Neoplasms | 1 | 2012 | 7 | 0.030 |
Why?
|
Positive Regulatory Domain I-Binding Factor 1 | 1 | 2012 | 3 | 0.030 |
Why?
|
Ki-1 Antigen | 1 | 2012 | 3 | 0.030 |
Why?
|
B7-1 Antigen | 1 | 2012 | 3 | 0.030 |
Why?
|
LIM Domain Proteins | 1 | 2012 | 3 | 0.030 |
Why?
|
In Situ Hybridization | 1 | 2012 | 6 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2012 | 15 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 2012 | 6 | 0.030 |
Why?
|
NF-kappa B | 1 | 2012 | 11 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 1 | 2012 | 32 | 0.030 |
Why?
|
Hepatovirus | 2 | 1985 | 2 | 0.030 |
Why?
|
Hepatitis B Antigens | 2 | 1985 | 2 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2013 | 322 | 0.020 |
Why?
|
Coproporphyrins | 1 | 1990 | 1 | 0.020 |
Why?
|
Porphyrins | 1 | 1990 | 1 | 0.020 |
Why?
|
Photosensitivity Disorders | 1 | 1990 | 3 | 0.020 |
Why?
|
Infant Nutritional Physiological Phenomena | 1 | 1970 | 6 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 1970 | 27 | 0.020 |
Why?
|
Morphine | 1 | 2009 | 8 | 0.020 |
Why?
|
Urinary Bladder Diseases | 1 | 2009 | 5 | 0.020 |
Why?
|
Bisexuality | 1 | 2009 | 12 | 0.020 |
Why?
|
Urination Disorders | 1 | 2009 | 10 | 0.020 |
Why?
|
Atazanavir Sulfate | 1 | 2008 | 5 | 0.020 |
Why?
|
Models, Statistical | 1 | 2009 | 177 | 0.020 |
Why?
|
Kidney Diseases | 1 | 2008 | 53 | 0.020 |
Why?
|
Hepatolenticular Degeneration | 2 | 1970 | 3 | 0.020 |
Why?
|
Insulin | 1 | 2009 | 205 | 0.020 |
Why?
|
Vasoconstriction | 2 | 1997 | 3 | 0.020 |
Why?
|
Rats | 2 | 1997 | 29 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2009 | 268 | 0.020 |
Why?
|
Outcome Assessment (Health Care) | 1 | 2007 | 228 | 0.020 |
Why?
|
Animals | 2 | 1997 | 259 | 0.020 |
Why?
|
Viral Hepatitis Vaccines | 1 | 1985 | 1 | 0.020 |
Why?
|
Fetal Diseases | 1 | 1985 | 8 | 0.020 |
Why?
|
Hepatitis B Antibodies | 1 | 1985 | 6 | 0.020 |
Why?
|
Immunization, Passive | 1 | 1985 | 3 | 0.020 |
Why?
|
Growth Disorders | 1 | 1985 | 1 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2005 | 49 | 0.020 |
Why?
|
Body Height | 1 | 1985 | 62 | 0.020 |
Why?
|
Fistula | 1 | 1984 | 1 | 0.010 |
Why?
|
Rectal Fistula | 1 | 1984 | 1 | 0.010 |
Why?
|
Abscess | 1 | 1984 | 6 | 0.010 |
Why?
|
Probability | 1 | 2004 | 79 | 0.010 |
Why?
|
Cholestasis, Extrahepatic | 1 | 1983 | 1 | 0.010 |
Why?
|
Cholestasis | 1 | 1983 | 1 | 0.010 |
Why?
|
Diagnostic Techniques, Surgical | 1 | 1983 | 1 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 1983 | 60 | 0.010 |
Why?
|
Cystic Fibrosis | 2 | 1970 | 8 | 0.010 |
Why?
|
Cyclic AMP | 1 | 1997 | 1 | 0.010 |
Why?
|
Serotonin Antagonists | 1 | 1997 | 1 | 0.010 |
Why?
|
Serotonin Receptor Agonists | 1 | 1997 | 1 | 0.010 |
Why?
|
8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 1997 | 1 | 0.010 |
Why?
|
Theophylline | 1 | 1997 | 3 | 0.010 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 1997 | 2 | 0.010 |
Why?
|
Rats, Wistar | 1 | 1997 | 3 | 0.010 |
Why?
|
Pulmonary Artery | 1 | 1997 | 3 | 0.010 |
Why?
|
Calcimycin | 1 | 1995 | 1 | 0.010 |
Why?
|
Inositol Phosphates | 1 | 1995 | 1 | 0.010 |
Why?
|
Endothelins | 1 | 1995 | 1 | 0.010 |
Why?
|
In Vitro Techniques | 1 | 1995 | 5 | 0.010 |
Why?
|
Muscle, Smooth | 1 | 1995 | 3 | 0.010 |
Why?
|
Kinetics | 1 | 1995 | 12 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 1995 | 8 | 0.010 |
Why?
|
Cells, Cultured | 1 | 1995 | 12 | 0.010 |
Why?
|
Isomerism | 1 | 1990 | 3 | 0.010 |
Why?
|
Syndrome | 1 | 1990 | 28 | 0.010 |
Why?
|
Carbohydrate Metabolism, Inborn Errors | 1 | 1970 | 1 | 0.010 |
Why?
|
Galactosemias | 1 | 1970 | 1 | 0.010 |
Why?
|
Bile | 1 | 1970 | 4 | 0.010 |
Why?
|
Tyrosine | 1 | 1970 | 2 | 0.010 |
Why?
|
India | 1 | 1970 | 13 | 0.010 |
Why?
|
Celiac Disease | 1 | 1970 | 1 | 0.010 |
Why?
|
Esophageal Atresia | 1 | 1970 | 1 | 0.010 |
Why?
|
Hyperbilirubinemia, Hereditary | 1 | 1970 | 1 | 0.010 |
Why?
|
Intestinal Atresia | 1 | 1970 | 1 | 0.010 |
Why?
|
Megacolon | 1 | 1970 | 1 | 0.010 |
Why?
|
Protein-Losing Enteropathies | 1 | 1970 | 1 | 0.010 |
Why?
|
Biliary Tract | 1 | 1970 | 2 | 0.010 |
Why?
|
Duodenal Diseases | 1 | 1970 | 3 | 0.010 |
Why?
|
Intestinal Obstruction | 1 | 1970 | 2 | 0.010 |
Why?
|
Constipation | 1 | 1970 | 4 | 0.010 |
Why?
|
Peptic Ulcer | 1 | 1970 | 14 | 0.010 |
Why?
|
Intestinal Perforation | 1 | 1970 | 8 | 0.010 |
Why?
|
Pancreatitis | 1 | 1970 | 50 | 0.010 |
Why?
|
Body Weight | 1 | 1970 | 219 | 0.010 |
Why?
|
Fissure in Ano | 1 | 1984 | 1 | 0.000 |
Why?
|
Proctocolitis | 1 | 1984 | 1 | 0.000 |
Why?
|
Puberty | 1 | 1985 | 58 | 0.000 |
Why?
|